Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and improve content delivery [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - The current severe influenza wave highlights the urgent need for broad-spectrum antivirals that can effectively target all influenza viruses and other seasonal respiratory viruses, including RSV and Coronaviruses [1] Company Summary - NanoViricides, Inc. is positioned as a clinical stage leader in the development of innovative broad-spectrum antiviral drugs that are designed to be effective against viruses [1] - The company emphasizes the significance of its antiviral solutions in light of the CDC's classification of this year's flu season as "moderately severe" [1]

Company Overview - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology that viruses cannot escape [2][4] - The company has developed NV-387, a novel antiviral drug that has completed Phase I human clinical trials and is preparing for a Phase II trial for treating MPox in Africa [4] - Additional clinical trials for NV-387 are planned for RSV, Influenza, COVID, and other respiratory infections, with expectations for efficacy against Measles virus as well [4] - The company also developed NV-HHV-1 for herpesvirus infections and NV-HIV-1 for HIV/AIDS treatment [4] - The overall market size for NV-387, NV-HHV-1, and NV-HIV-1 is estimated to be between $20 to $30 billion [4] Event Participation - NanoViricides will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City [2] - Anil R. Diwan, President & Executive Chairman, will host one-on-one meetings during the conference from 9:00 A.M. to 3:00 P.M. (ET) [3]